RBC Capital Reiterates Outperform on Ionis Pharmaceuticals, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating for Ionis Pharmaceuticals, maintaining a price target of $70.
September 26, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Ionis Pharmaceuticals, maintaining a price target of $70, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a maintained price target of $70 by RBC Capital suggests positive sentiment and confidence in Ionis Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price as it reflects analyst confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100